-
公开(公告)号：US20220411413A1
公开(公告)日：2022-12-29
申请号：US17872680
申请日：2022-07-25
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: C07D405/14 , C07D209/46 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D401/06 , C07D405/04 , A61K31/4035 , A61K31/4155 , A61K31/4439 , A61K31/13 , A61K31/325 , A61K31/445 , A61K31/55 , A61K31/045 , A61K31/4406
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.
The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.-
公开(公告)号：US20190241547A1
公开(公告)日：2019-08-08
申请号：US16209349
申请日：2018-12-04
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: C07D405/14 , C07D209/46 , A61K31/4439 , A61K31/4406 , A61K31/045 , A61K31/55 , A61K31/445 , A61K31/325 , A61K31/13 , C07D401/06 , A61K31/4155 , A61K31/4035 , C07D403/10 , C07D403/04 , C07D401/14 , C07D401/10 , C07D405/04
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US20170121308A1
公开(公告)日：2017-05-04
申请号：US15318552
申请日：2015-06-11
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masaki OGINO , Eiji KIMURA , Shinkichi SUZUKI , Tomoko ASHIZAWA , Toshihiro IMAEDA , Ikuo FUJIMORI , Ryosuke ARAI
IPC: C07D401/10 , C07D213/81 , C07D405/14
CPC classification number: C07D401/10 , A61K31/44 , A61K31/4439 , A61K31/444 , C07D213/81 , C07D401/14 , C07D405/12 , C07D405/14
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.
-
公开(公告)号：US20170100373A1
公开(公告)日：2017-04-13
申请号：US15388834
申请日：2016-12-22
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: A61K31/4035
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US20170027921A1
公开(公告)日：2017-02-02
申请号：US15291769
申请日：2016-10-12
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: A61K31/4439 , A61K31/4155 , A61K31/4035
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
Abstract translation: 其中每个符号如说明书中所述或其盐。
-
Patent Agency Ranking
公开(公告)号：US20160376244A1
公开(公告)日：2016-12-29
申请号：US15190642
申请日：2016-06-23
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA
IPC: C07D265/22 , C07D413/06 , C07D491/107 , C07D413/04 , C07F7/02 , C07D471/04 , C07D413/14 , C07D413/10
CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
Abstract translation: 其中每个符号如所附的说明中所定义。
-
17.发明申请公开(公告)号：US20190248776A1
公开(公告)日：2019-08-15
申请号：US16394762
申请日：2019-04-25
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA
IPC: C07D413/14 , C07D491/107 , C07D471/04 , C07D417/06 , C07D413/10 , C07D413/06 , C07D265/22 , C07F7/02 , C07D413/04 , C07F7/08 , A61P25/28 , C07D417/10
CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
公开(公告)号：US20180362516A1
公开(公告)日：2018-12-20
申请号：US16113635
申请日：2018-08-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Takuto KOJIMA
IPC: C07D413/14 , C07D413/06 , C07D471/04 , C07D491/107 , C07D413/04 , C07F7/02 , C07D417/06 , C07D265/22 , C07F7/08 , C07D417/10 , A61P25/28 , C07D413/10
CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
公开(公告)号：US20180050996A1
公开(公告)日：2018-02-22
申请号：US15799379
申请日：2017-10-31
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Takuto KOJIMA
IPC: C07D265/22 , C07F7/02 , C07D491/107 , C07D471/04 , C07D417/06 , C07D413/14 , C07D413/10 , C07D413/06 , C07D413/04
CPC classification number: C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
公开(公告)号：US20170258764A1
公开(公告)日：2017-09-14
申请号：US15608565
申请日：2017-05-30
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Masami YAMADA , Shinkichi SUZUKI , Takahiro SUGIMOTO , Minoru NAKAMURA , Hiroki SAKAMOTO , Makoto KAMATA
IPC: A61K31/4035 , A61K31/045 , A61K31/4406
CPC classification number: C07D405/14 , A61K31/045 , A61K31/13 , A61K31/325 , A61K31/4035 , A61K31/4155 , A61K31/4406 , A61K31/4439 , A61K31/445 , A61K31/55 , C07D209/46 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D471/04
Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
-
-
-
-
-
-
-
-
-
Search Results
25
records
(took 0.026 seconds)
